The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

被引：7
|
作者：
Santana-Davila, Rafael [1 ]
Chow, Laura Q. M. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 03期
关键词：
chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; NSCLC; treatment naive; PACLITAXEL PLUS CARBOPLATIN; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/fon-2017-0124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
  • [21] Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer
    Wu, HG
    Choy, H
    ONCOLOGY-NEW YORK, 2002, 16 (09): : 13 - 18
  • [22] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Fidias, Panos M.
    Dakhil, Shaker R.
    Lyss, Alan P.
    Loesch, David M.
    Waterhouse, David M.
    Bromund, Jane L.
    Chen, Ruqin
    Hristova-Kazmierski, Maria
    Treat, Joseph
    Obasaju, Coleman K.
    Marciniak, Martin
    Gill, John
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 591 - 598
  • [23] Front-line therapy in lung cancer with mutations in EGFR
    Lorenza Landi
    Federico Cappuzzo
    Nature Reviews Clinical Oncology, 2011, 8 : 571 - 573
  • [24] Front-line therapy in lung cancer with mutations in EGFR
    Landi, Lorenza
    Cappuzzo, Federico
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (10) : 571 - 573
  • [25] Second-line therapy for advanced non-small-cell lung cancer
    Hann C.L.
    Brahmer J.R.
    Current Oncology Reports, 2006, 8 (4) : 243 - 247
  • [26] Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer.
    Treat, J
    McCleod, M
    Mintzer, D
    Christiansen, N
    Bonomi, P
    Monberg, M
    Taylor, L
    Obasaju, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 648S - 648S
  • [27] Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer
    Awada, Gil
    Klastersky, Jean
    CURRENT OPINION IN ONCOLOGY, 2018, 30 (02) : 98 - 104
  • [28] A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer
    Giannakakis, T
    Kakolyris, S
    Theodoropoulos, E
    Kouroussis, C
    Michailakis, E
    Papadouris, S
    Tsitoura, M
    Kalbakis, K
    Souglakos, J
    Agelaki, S
    Vardakis, N
    Georgoulias, V
    ANTICANCER RESEARCH, 2002, 22 (6B) : 3743 - 3748
  • [29] Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
    Besse, B
    Soria, JC
    Le Chevalier, T
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 997 - 998
  • [30] Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
    West, H. L.
    Wakelee, H. A.
    Perry, M. C.
    Belt, R. J.
    Chen, R.
    Obasaju, C.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 850 - 856
12345